Ainos Inc. (AIMD)

OTCMKTS: AIMD · Delayed Price · USD
2.52
+0.02 (0.80%)
Aug 16, 2022 4:00 PM - Market closed
0.80%
Market Cap 24.26M
Revenue (ttm) 679,643
Net Income (ttm) -5.45M
Shares Out 9.63M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,217
Open 2.40
Previous Close 2.50
Day's Range 2.40 - 2.66
52-Week Range 1.25 - 18.00
Beta 1.08
Analysts n/a
Price Target n/a
Earnings Date n/a

About AIMD

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation b... [Read more...]

Industry Pharmaceutical Preparation Manufacturing
Founded 1984
Employees 34
Stock Exchange OTCMKTS
Ticker Symbol AIMD
Full Company Profile

News

Ainos Reports Second Quarter 2022 Financial Results

SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-...

Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-...

Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / August 8, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose i...

Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19

Hamsters Receiving Ainos' VELDONA Formulation Demonstrate Protection from COVID-19 Based on Prespecified Indicators of Clinical Outcomes SAN DIEGO , June 27, 2022  /PRNewswire/ -- Ainos, Inc. (OTC PINK:...

Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan

SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose in...

Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infe...

SAN DIEGO, CA / ACCESSWIRE / December 7, 2021 / Ainos, Inc. ("we", "our", or the "company"), (OTC PINK:AIMD), a diversified healthcare company engaged in the discovery and development of pharmaceutical,...